January 2026 Research Update

This month added a clearer warning signal that pregnancy outcomes in idiopathic inflammatory myopathies can shift with changes in disease activity during pregnancy, not just with how things look at conception. In a small Portuguese series, adverse pregnancy outcomes were reported only in pregnancies where the mother had a flare, while pregnancies without flares did not have these complications. This helps connect day-to-day disease control during pregnancy with outcomes people care about, such as miscarriage, stillbirth, and growth problems for the baby. [1]

Half of the pregnancies in this report had an adverse outcome, including miscarriages, one stillbirth, and one case of fetal growth restriction with a small-for-gestational-age newborn. Even though most pregnancies started when the disease was in remission, remission did not guarantee an uneventful course, which highlights how unpredictable the disease can be across months of pregnancy. The most severe outcomes clustered in a mother with antisynthetase syndrome and very high anti-Jo-1 antibody levels, but this was based on very small numbers. [1]

The report also noted that early, unplanned exposure to certain medicines (mycophenolate and cyclophosphamide) occurred in a pregnancy that ended in miscarriage. Because this is a retrospective description without a comparison group, it cannot prove which factors caused which outcomes, but it does map out the kinds of complications that were seen alongside flares and medication issues in routine care. [1]

For patients, this mainly adds shared experience data rather than changing anything immediately, because it is a small retrospective series. It helps clarify that the course of disease during pregnancy (especially whether flares happen) may be important for pregnancy outcomes, and that being in remission at conception may not tell the whole story about what will happen later. What remains uncertain is how strongly this pattern holds across larger groups, different myositis subtypes, and different treatment approaches, since only 12 pregnancies were included. [1]

This month, studies looking at myositis-related interstitial lung disease (lung inflammation and scarring) moved the picture forward in two connected ways: a potential short-term blood signal in people, and a possible immune mechanism in lab models. In anti-MDA5 dermatomyositis with lung disease, IFN-lambda3 levels dropping within 1 month went along with better disease control over the next year, while persistently high levels went along with relapse or death. In mouse and cell experiments, baricitinib reduced lung inflammation and scarring and also reduced immune web-like structures (NETs) and a specific immune alarm pathway (cGAS-STING), which the researchers linked to scarring-like changes in lung cells. [2] [3]

In the human cohort (24 patients with anti-MDA5-positive dermatomyositis lung disease), IFN-lambda3 fell sharply by 1 month in the group with good control, but stayed high in the group with poor control. IFN-lambda3 levels measured at 1 month were also higher in those who later died within 1 year, while other commonly followed blood markers in this setting did not show short-term change. This suggests IFN-lambda3 might be a more responsive early signal of how the lung disease is behaving after treatment starts, at least in this specific subtype. [2]

In laboratory research, baricitinib (a JAK inhibitor medicine) was tested in a mouse model of myositis-associated lung disease and in lung cells exposed to NETs. The researchers reported less lung inflammation and fibrosis in treated mice, and in cells they saw that NETs pushed lung cells toward changes linked with scarring, while baricitinib counteracted those changes and reduced activation of the cGAS-STING pathway. These findings do not show what will happen in patients, but they offer a possible explanation for how immune activity could drive lung scarring and where a medicine might interrupt that process. [3]

For patients, the IFN-lambda3 finding may matter in the future because it raises the possibility of a blood test that reflects short-term lung disease control in anti-MDA5 dermatomyositis, but it is not yet established for routine use and was studied in only 24 people. The baricitinib work is earlier-stage research in mice and cells, so it mainly helps explain potential immune drivers of lung damage (NETs and cGAS-STING) rather than providing a proven treatment result in humans. What remains uncertain is whether IFN-lambda3-guided monitoring improves outcomes, and whether the lab findings predict benefits or risks in real-world myositis-related lung disease. [2] [3]

This month reinforced that polymyositis and related inflammatory muscle diseases do not always show up in a single, straightforward way, and that context matters for recognition. One case report described inflammatory muscle disease in an older adult despite normal CK (a common muscle blood test), diagnosed using antibody testing, muscle imaging, and biopsy. Another case report described polymyositis-like inflammation as a severe immune side effect after a PD-1 cancer immunotherapy drug, with muscle breakdown and heart involvement that improved after intensive steroid treatment and supportive care. A population study looked at chronic rhinosinusitis alongside autoimmune diseases including polymyositis, but did not report results in the available abstract. [4] [5] [6]

In the older adult case, the key practical point was that normal CK did not rule out inflammatory myopathy when the person had worsening weakness and functional decline. The diagnosis was supported by a myositis-related antibody (Mi-2), muscle imaging showing muscle swelling, and a muscle biopsy showing immune-related changes, and the patient improved with corticosteroids plus mycophenolate mofetil. This single case cannot predict what will happen for others, but it illustrates why some people need a more complete evaluation when symptoms and basic labs do not match. [4]

In the cancer immunotherapy case, polymyositis occurred as part of a multi-organ immune reaction after sintilimab, alongside muscle breakdown (rhabdomyolysis) and signs of heart muscle involvement. The patient improved quickly after high-dose steroid pulse treatment and supportive care, and symptoms resolved at short follow-up, although no antibody testing or muscle biopsy was done. This report adds to awareness that muscle inflammation can be part of immune-related side effects in some people receiving checkpoint inhibitors, but it remains a single-patient experience. [5]

The population study focused on whether chronic rhinosinusitis (long-lasting sinus inflammation) occurs more often alongside autoimmune diseases, noting prior evidence that includes polymyositis and that sex-specific patterns have not been well examined. However, the available abstract did not provide the study results or effect sizes, so it mainly signals that this possible link is being explored in routine-care datasets. This may become more meaningful if future publications report clear numbers and whether the pattern differs by sex. [6]

For patients and caregivers, these reports mainly add context for understanding why diagnosis or recognition can sometimes be delayed or complicated. The normal-CK case clarifies that common blood tests may not capture every presentation, especially in older adults, while the immunotherapy case clarifies that polymyositis-like symptoms can appear as an uncommon but serious medication-related immune reaction in cancer care. The sinusitis study may matter later if results show a consistent pattern that helps explain symptoms outside the muscles, but right now the abstract does not provide findings to apply. [4] [5] [6]

This month added a clearer biological story connecting muscle weakness with how muscle cells manage their energy factories (mitochondria). In experiments, loss of a protein called CTRP1 disrupted mitochondrial health and made it harder for muscle cells to form and repair muscle fibers, leading to weaker muscles in mice. In human muscle biopsies, CTRP1 levels were lower in polymyositis and other muscle diseases, and the decrease tracked with greater disease severity. [7]

When CTRP1 was missing in muscle cells and in muscle-specific CTRP1 knockout mice, the study reported poorer muscle fiber formation, smaller muscle fibers, and reduced muscle strength, along with abnormal mitochondria that were less efficient. The researchers linked this to a problem with recruiting DRP1, a protein involved in keeping mitochondria working properly. Restoring CTRP1, or experimentally transplanting mitochondria, improved mitochondrial function and supported muscle cell differentiation in these models. [7]

In muscle biopsies from people with polymyositis, dermatomyositis, and Duchenne muscular dystrophy, CTRP1 expression was reported to decrease as disease severity increased. This does not prove CTRP1 changes cause disease in humans, but it supports the idea that mitochondrial quality control may be part of the shared muscle damage and repair problem across different myopathies. It also raises the possibility that CTRP1 could become a research marker of disease severity, although that is not yet established for clinical use. [7]

For patients, this is early-stage research that helps explain possible reasons muscles can feel weak and have trouble recovering in polymyositis. It may matter later if CTRP1-related pathways lead to new ways to measure disease activity or support muscle repair, but the work does not test a treatment in people with polymyositis. What remains uncertain is how much changing CTRP1 levels would change symptoms or function in humans, since much of the evidence comes from cells and mice, with human biopsy findings showing correlation with severity. [7]